Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Intangibles (2022 - 2025)

Historic Intangibles for Catalyst Pharmaceuticals (CPRX) over the last 4 years, with Q3 2025 value amounting to $227.7 million.

  • Catalyst Pharmaceuticals' Intangibles changed 0.0% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $227.7 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Intangibles stood at $227.7 million, which was down 0.0% from $227.7 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Intangibles registered a high of $227.7 million during Q4 2023, and its lowest value of $32.5 million during Q4 2022.
  • Its 4-year average for Intangibles is $182.4 million, with a median of $227.7 million in 2023.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Intangibles skyrocketed by 60127.81% in 2023, and later changed by 0.0% in 2024.
  • Over the past 4 years, Catalyst Pharmaceuticals' Intangibles (Quarter) stood at $32.5 million in 2022, then soared by 601.28% to $227.7 million in 2023, then changed by 0.0% to $227.7 million in 2024, then changed by 0.0% to $227.7 million in 2025.
  • Its last three reported values are $227.7 million in Q3 2025, $227.7 million for Q2 2025, and $227.7 million during Q1 2025.